CAMP4 Therapeutics Corporation

Company overview

CAMP4 Therapeutics Corporation is a clinical-stage biopharmaceutical company discovering and developing RNA-targeting therapeutics that upregulate gene expression to restore healthy protein levels for genetic diseases. The lead candidate is CMP-002 for SYNGAP1-related developmental and epileptic encephalopathy (SYNGAP1 DEE). The primary focus is on central nervous system (CNS) diseases where haploinsufficiency is a core mechanism, with additional discovery programs in other DEE indications.

Technology and approach

• RAP Platform: maps and characterizes regulatory RNAs (regRNAs) that control gene transcription.
• Mechanism: uses regRNAs as targets for antisense oligonucleotides (ASOs) that bind regRNAs to increase mRNA and protein production.
• Delivery and scope: employs validated ASO chemistries with tissue-targeting considerations; CNS programs use intrathecal delivery for brain distribution.
• Data assets: mapping of tens of thousands of regRNA sequences analyzed with a proprietary algorithm (EPIC) to identify gene-specific regRNA targets; mapping performed in primary human cell lines.

Lead programs and pipeline status

• CMP-002 (SYNGAP1)

  • Strategy: intrathecal ASO targeting a regRNA to increase SYNGAP1 transcription and protein levels.
  • Preclinical data: dose-dependent increase in SYNGAP protein in humanized SYNGAP1 mice (up to ~1.7-fold); improved disease-relevant behaviors in haploinsufficient mice; broad brain distribution and dose-linear brain concentrations in cynomolgus monkeys.
  • Development plan: GLP toxicology ongoing to support a global Phase 1/2 trial, potentially starting in the second half of 2026.

• CMP-001 (urea cycle disorders)

  • Strategy: intrathecal or systemic ASO to amplify CPS1 expression to enhance ureagenesis and ammonia handling.
  • Status: completed Phase 1 healthy volunteer studies (SAD and MAD cohorts) with a favorable safety profile; pharmacokinetics showed dose-dependent exposure.
  • 2025 development decision: strategic pause on new investment in CMP-001 to prioritize CMP-002; pursuing partnership opportunities to continue CMP-001.

• Other discovery programs: ongoing exploration in additional DEE indications and broader CNS targets; strategic collaboration with GSK to extend RAP Platform applications beyond CNS.

Collaborations and licensing

• GlaxoSmithKline (GSK) collaboration (entered December 2025)

  • Research, collaboration and license agreement to identify, validate, and develop ASO therapies targeting regRNAs across multiple targets.
  • GSK holds an exclusive worldwide license to research, develop, manufacture, and commercialize licensed compounds/products directed to the collaboration targets.
  • Financial terms: $17.5 million upfront; potential milestone payments up to $440 million; tiered royalties on net sales (low- to mid-single digits); governance and data transfer terms; termination rights for either party under specified circumstances.

• Whitehead Institute license (in-licensed technology, since 2019; amended 2021 and 2023)

  • Worldwide royalty-bearing license under certain patent rights to develop and commercialize products and processes in human/animal therapeutics and diagnostics, with research-use carve-outs and government rights.
  • Financial terms: upfront license issuance fee $0.1 million; aggregate annual maintenance fees $0.4 million through 12/31/2025; patent-related filing and maintenance fees $0.5 million through 12/31/2025; potential development milestones up to $1.9 million (paid to date $0.2 million); tiered royalties on net sales if commercialized.

Intellectual property

• Portfolio (as of 12/31/2025): 25 patent families
  • U.S. issued patents (owned): 4
  • In-licensed issued U.S. patents: 14
  • In-licensed foreign issued patents: 27
  • U.S. pending patent applications (owned or in-licensed): 23
  • Foreign pending patent applications (owned or in-licensed): 66
  • PCT application owned or in-licensed: 1 (not yet entered national phase)
• Key protections: platform-related patents on regRNA targeting methods, enhancer-promoter mapping, and condensate-dependent transcription; program-related patents for CMP-002, CMP-001, and regRNA compositions/methods.
• Term considerations: patent terms generally 20 years from earliest non-provisional filing, with possible extensions (e.g., patent term adjustments, Hatch-Waxman extensions); expected expiries for CMP-002 and CMP-001 families around 2042–2045, subject to extensions.

Manufacturing and operations

• No internal manufacturing facilities; relies on third-party contract manufacturers (CMOs) for clinical and potential commercial supply.
• Packaging, labeling, storage, and distribution are outsourced.
• Operational emphasis is on clinical development and pipeline expansion, with partnerships used to fund and advance programs.

Regulatory and market context

• Regulatory framework: U.S. and EU processes for INDs/NDAs, cGMP, GLP/GCP, clinical trial approvals, and post-approval requirements (REMS, labeling, post-approval studies).
• Orphan and pediatric pathways: uses orphan designation and pediatric regulatory pathways, including the rare pediatric disease priority review voucher program and PREA/exclusivity considerations.
• Competitive landscape: active competition in CNS and RNA-targeting therapeutics. Competitors include Stoke Therapeutics, Acadia Pharmaceuticals (co-development of SYNGAP1 products), Praxis Precision Medicines, GondolaBio, Tevard, Regel Therapeutics, Quiver Bioscience, and others pursuing antisense and RNA-targeted approaches.

Financial positioning

• No products approved for sale to date.
• The company has incurred significant losses since inception and expects to incur losses for the foreseeable future.
• Capital needs: requires substantial additional capital to finance operations; failure to obtain capital could delay or terminate programs.
• Financing from partnerships: GSK upfront payment of $17.5 million and up to $440 million in potential development and commercial milestones, plus potential royalties.
• Operational implications: reliance on third-party financing and collaborations introduces risks related to dilution, restrictions, and partner-driven development.

Summary

CAMP4 is building an RNA-regulation platform (RAP) to upregulate gene expression with programmable ASOs, focused on haploinsufficient CNS diseases. The lead candidate, CMP-002, targets SYNGAP1-related DEE with preclinical evidence of increased SYNGAP protein and improved disease-relevant behaviors; GLP toxicology is underway to support a potential global Phase 1/2 trial in 2026. CMP-001, an earlier UCD program, is on strategic pause while the company prioritizes CMP-002 and seeks partners. Strategic agreements with GSK and the Whitehead Institute support development and provide funding and IP access while creating dependencies on partner-driven development and commercialization. The company maintains a broad patent portfolio and continues to seek capital to advance its pipeline.